Cann Group Limited (CNGGF) Stock
Cann Group Limited specializes in the end-to-end process of bringing medicinal cannabis to market. Its activities span from genetic development and cultivation to product manufacturing, clinical trials, and ultimately, the supply of therapeutic cannabis for both Australian consumption and international export.
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Peer Comparison
About Cann Group Limited
Cann Group Limited specializes in the end-to-end process of bringing medicinal cannabis to market. Its activities span from genetic development and cultivation to product manufacturing, clinical trials, and ultimately, the supply of therapeutic cannabis for both Australian consumption and international export. The company holds specific licenses enabling it to conduct research and grow cannabis for human medicinal and scientific study. Founded in 2014, Cann Group Limited operates out of its base in Port Melbourne, Australia.
Cann Group Limited (CNGGF) stock trades at $0.00 with a market capitalization of $2.40M. The stock is valued at a price-to-earnings (P/E) ratio of 0.27, price-to-book of 0.07, price-to-sales of 0.18. Over the past 52 weeks the stock has ranged between $0.00 and $0.02, and currently trades 100.0% below its 52-week high.
On profitability, Cann Group Limited generates a return on equity (ROE) of 733.33% — well above the market average, a sign of a high-quality business, return on capital employed of -31.90%, an operating margin of -69.23%, a net profit margin of -169.23%.
Official website: www.canngrouplimited.com